Compare Terumo Corp. with Similar Stocks
Dashboard
1
Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 36.60
2
Healthy long term growth as Net Sales has grown by an annual rate of 10.50%
3
Positive results in Jun 25
4
With ROE of 8.55%, it has a attractive valuation with a 2.81 Price to Book Value
5
Majority shareholders : FIIs
Stock DNA
Pharmaceuticals & Biotechnology
JPY 3,260,192 Million (Large Cap)
33.00
NA
0.00%
-0.04
9.09%
2.27
Revenue and Profits:
Net Sales:
259,965 Million
(Quarterly Results - Jun 2025)
Net Profit:
41,843 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-18.1%
0%
-18.1%
6 Months
-19.77%
0%
-19.77%
1 Year
-26.95%
0%
-26.95%
2 Years
-19.31%
0%
-19.31%
3 Years
-46.38%
0%
-46.38%
4 Years
-51.87%
0%
-51.87%
5 Years
-53.64%
0%
-53.64%
Terumo Corp. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
10.50%
EBIT Growth (5y)
10.47%
EBIT to Interest (avg)
36.60
Debt to EBITDA (avg)
0.20
Net Debt to Equity (avg)
-0.03
Sales to Capital Employed (avg)
0.63
Tax Ratio
24.25%
Dividend Payout Ratio
32.91%
Pledged Shares
0
Institutional Holding
0.02%
ROCE (avg)
11.10%
ROE (avg)
8.48%
Valuation key factors
Factor
Value
P/E Ratio
33
Industry P/E
Price to Book Value
2.81
EV to EBIT
21.22
EV to EBITDA
14.37
EV to Capital Employed
2.88
EV to Sales
3.67
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
13.55%
ROE (Latest)
8.55%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot : Sep 2025
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 4 Foreign Institutions (0.02%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
259,965.00
263,936.00
-1.50%
Operating Profit (PBDIT) excl Other Income
74,669.00
59,430.00
25.64%
Interest
1,278.00
2,423.00
-47.26%
Exceptional Items
0.00
0.00
Consolidate Net Profit
41,843.00
18,356.00
127.95%
Operating Profit Margin (Excl OI)
205.70%
143.80%
6.19%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is -1.50% vs 0.15% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 127.95% vs -48.17% in Mar 2025
Annual Results Snapshot (Consolidated) - Mar'25
Mar'25
Mar'24
Change(%)
Net Sales
1,036,171.00
921,863.00
12.40%
Operating Profit (PBDIT) excl Other Income
264,471.00
210,941.00
25.38%
Interest
2,016.00
2,065.00
-2.37%
Exceptional Items
-24,728.00
-2,008.00
-1,131.47%
Consolidate Net Profit
116,978.00
106,374.00
9.97%
Operating Profit Margin (Excl OI)
172.80%
145.60%
2.72%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2025 is 12.40% vs 12.39% in Mar 2024
Consolidated Net Profit
YoY Growth in year ended Mar 2025 is 9.97% vs 19.09% in Mar 2024
About Terumo Corp. 
Terumo Corp.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






